Estonia - Esti - Ravimiamet

pharmaswiss ceska republika s.r.o. - oksükodoon - toimeainet prolongeeritult vabastav tablett - 10mg 50tk; 10mg 60tk; 10mg 100tk; 10mg 28tk; 10mg 40tk; 10mg 56tk; 10mg 30tk; 10mg 20tk

Estonia - Esti - Ravimiamet

pharmaswiss ceska republika s.r.o. - oksükodoon - toimeainet prolongeeritult vabastav tablett - 5mg 20tk; 5mg 30tk; 5mg 50tk; 5mg 100tk; 5mg 60tk; 5mg 10tk; 5mg 56tk; 5mg 40tk; 5mg 112tk

Estonia - Esti - Ravimiamet

sandoz pharmaceuticals d.d. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 10mg+10mg 10tk; 10mg+10mg 28tk

Estonia - Esti - Ravimiamet

sandoz pharmaceuticals d.d. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 20mg+10mg 30tk; 20mg+10mg 10tk; 20mg+10mg 90tk

Uni Eropa - Esti - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - migreenihäired - valuvaigistid - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Estonia - Esti - Ravimiamet

teva b.v. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 10mg+10mg 28tk; 10mg+10mg 10tk; 10mg+10mg 60tk; 10mg+10mg 30tk

Estonia - Esti - Ravimiamet

teva b.v. - rosuvastatiin+esetimiib - õhukese polümeerikattega tablett - 20mg+10mg 60tk; 20mg+10mg 28tk; 20mg+10mg 30tk; 20mg+10mg 10tk

Uni Eropa - Esti - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitasoonvesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. pärast algatamist ravi pioglitazone, patsiente tuleks läbi vaadata pärast 3 kuni 6 kuud hinnata piisavust ravi (e. vähendada hba1c). patsientidel, kes ei näita piisava vastuse, pioglitazone tuleks lõpetada. arvestades võimalikke riske pikaajalise ravi, arstid tuleks kinnitada järgmiste korraliste kommentaare, mis kasu pioglitazone on säilinud (vt lõik 4.

Uni Eropa - Esti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - asatsitidiin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastilised ained - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Uni Eropa - Esti - EMA (European Medicines Agency)

accord healthcare s.l.u. - lakosamiid - epilepsia - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.